Clinical trial enrolment rate in Alberta higher than national average

After being diagnosed with breast cancer in November 2011, Kathy Kammermayer has come a long way.

Her course of treatment included medications. One of them was Herceptin. It is often touted for its effectiveness, however, patients are also cautioned about the risk it presents: heart damage.

Read the full article...